查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年止血劑市場預測：按產品類型、配方、適應症、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383411

到 2030 年止血劑市場預測：按產品類型、配方、適應症、應用、最終用戶和地區進行的全球分析

Hemostats Market Forecasts to 2030 - Global Analysis By Product Type, Formulation, Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球止血劑市場規模將達到 27 億美元，預計 2030 年將達到 48 億美元，預測期內年複合成長率為 8.7%。

止血鉗是一種透過夾持、密封或壓迫血管、組織來控制出血的醫療器械。止血材料是外科手術中的寶貴工具，可確保手術場無血並協助準確、安全的介入。止血材料可防止過度出血，並最大限度地降低手術期間出血和併發症的風險。

根據美國心臟協會2020年7月發布的報告，美國年度冠狀動脈繞道手術繞道手術（CABG）手術量約24萬例。

手術數量增加

隨著世界人口的成長和高齡化，從心血管和整形外科手術到創傷和癌症相關手術等各個醫學領域對外科手術的需求持續增加。止血材料在這些手術期間控制出血方面發揮重要作用，有助於病人安全和手術成功。隨著手術技術的進步和手術選擇的擴大，對有效且高效的止血裝置的需求變得顯而易見。手術數量的增加凸顯了止血裝置在維持止血、減少失血和改善患者預後方面發揮的重要作用。

緊急情況下有限使用

止血材料對於手術過程中控制出血至關重要，但其應用在快速、高壓力的緊急情況下（例如創傷治療和戰地醫學）可能受到限制。在這種情況下，需要一種能夠可靠且幾乎立即止血的止血材料。需要複雜的使用程序或特殊條件的止血材料可能無法滿足此類危急情況的需求。克服這些限制需要開發專門的止血材料，旨在在緊急情況下快速有效地使用，以挽救生命並防止嚴重出血。

降低醫療成本

透過最大限度地減少出血、減少輸血需求和縮短手術時間，止血劑有助於降低醫療成本。這些經濟高效的解決方案可改善資源分配、減少術後併發症並改善患者治療效果。在醫療保健成本控制至關重要的環境中，兼具臨床療效和經濟效益的止血劑產品能夠很好地應對這些機會並獲得市場吸引力。

嚴格法規的變化

不斷變化的法規和日益嚴格的安全標準可能會影響止血劑的核准、配製和商業化。跟上不斷變化的法規可能既耗時又昂貴，導致市場進入延遲並增加開發成本。面臨的挑戰是滿足新的要求，同時保持產品的安全性和有效性。法規的不確定性和對全面文件的需求增加了開發過程的複雜性。這些因素可能會阻礙創新，限制新型止血解決方案的推出，並降低市場響應醫療保健專業人員和患者不斷變化的需求的能力。

COVID-19 的影響：

COVID-19大流行對止血材料市場產生了各種影響。危重手術和創傷護理領域對止血材料的需求仍然很高，但疫情擾亂了供應鏈並影響了某些產品的可得性。此外，選擇性手術被推遲或取消，暫時減少了整體市場需求。由於醫療機構專注於 COVID-19 治療，因此對止血等其他醫療需求的關注度出現了波動。然而，隨著維持穩健的醫療基礎設施的重要性和對緊急止血劑的需求變得更加清晰，以及隨著醫療保健系統適應未來的挑戰，大流行後市場將會成長，並可能增強彈性。

預計在預測期內基於凝血酶的止血劑市場將是最大的

基於凝血酶的止血劑市場預計將出現良好的成長。這些產品含有凝血酶，一種啟動血液凝固過程的酵素。當應用於出血部位時，基於凝血酶的止血劑會透過將可溶性纖維蛋白原轉化為不溶性纖維蛋白鏈來促進凝塊形成，最終形成穩定的血塊。其多功能性使其適用於各種外科手術，從心血管和整形外科手術到肝切除和創傷治療。以凝血酶為基礎的止血劑可快速、精確地控制出血，降低出血及其相關併發症的風險。基於凝血酶的止血材料具有實績的止血效果，在醫療領域備受信賴，從而提高了其在整個止血材料市場中的地位。

預計醫院領域在預測期內的年複合成長率最高。

預計醫院產業在預測期內將以最快的年複合成長率成長。從大型學術醫療中心到社區醫院，這些醫療機構在各種外科手術過程中都依賴止血材料來控制出血。止血材料是確保手術場無血的重要工具，以便醫療專業人員能夠準確、安全地進行手術。無論是擇期手術或急診手術，對手術介入的持續需求強調了醫院止血材料的重要性。此外，包括微創技術在內的先進手術技術的採用，進一步增加了對有效止血材料的需求，醫院繼續關注病患安全、成功的手術結果和業務開拓。止血材料市場。

比最大的地區

預計北美市場在預測期內將繼續佔據大部分市場佔有率。該地區擁有完善的醫療基礎設施、先進的醫療技術和大量的外科手術。從心血管手術和整形外科手術到創傷護理，各種醫學專業對止血材料和設備的需求仍然很高。嚴格的法規標準和對病人安全的關注正在推動創新止血解決方案的開發和採用。此外，慢性病的流行和高齡化進一步增加了對有效止血材料的需求。

複合年複合成長率最高的地區：

亞太地區在市場中發揮重要作用，預計在預測期內年複合成長率最高。醫療投資的增加、醫療基礎設施的擴建以及患者人數的增加為止血材料和設備的採用創造了有利的環境。隨著手術數量的增加，對有效止血解決方案的需求不斷增加，特別是中國和印度等國家。此外，該地區對負擔得起的醫療保健解決方案的關注、醫療旅遊的趨勢和獲得醫療保健的機會也正在推動市場成長。

免費客製化服務：

訂閱此報告的客戶將收到以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球止血材料市場：依產品類型

  • 基於凝血酶的止血劑
  • 氧化再生纖維素基止血材料
  • 複合止血材料
  • 纖維蛋白密封劑
  • 明膠止血材料
  • 膠原蛋白止血材料
  • 其他產品類型

第6章 全球止血劑市場：依配方分類

  • 基質和凝膠止血材料
  • 片材和墊片止血材料
  • 海綿止血材料
  • 粉末止血劑
  • 其他處方

第7章 全球止血劑市場：依適應症分類

  • 關閉
  • 外科手術

第8章 全球止血材料市場：依應用分類

  • 整形外科
  • 一般外科
  • 神經外科
  • 心血管外科
  • 重組手術
  • 婦科手術
  • 整形外科
  • 其他用途

第9章 全球止血材料市場：依最終用戶分類

  • 門診中心
  • 醫院
  • 診所
  • 社區健康保健
  • 其他最終用戶

第10章 全球止血材料市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Ethicon, Inc
  • Becton Dickinson and Company
  • Marine Polymer Technologies, Inc
  • Pfizer, Inc
  • Johnson & Johnson Services, Inc
  • Integra Lifesciences Corporation
  • Hemostatis LLC
  • Z-Medica LLC
  • Medtronic plc
  • Gelita Medical GmbH
  • Stryker Corporation
  • Baxter International, Inc
  • Teleflex Incorporated
  • Anika Therapeutics, Inc
  • B. Braun Melsungen AG
  • CR Bard, Inc.
Product Code: SMRC24260

According to Stratistics MRC, the Global Hemostats Market is accounted for $2.7 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Hemostats are medical instruments used to control bleeding by either clamping, sealing, or compressing blood vessels, tissues, or vessels. They are valuable tools in surgical procedures to ensure a bloodless surgical field, aiding in accurate and safe interventions. Hemostats help prevent excessive blood loss, minimizing the risk of hemorrhage and complications during surgery.

According to a report published by American Heart Association in July 2020, the annual number of Coronary Artery Bypass Graft (CABG) surgeries is around 240,000 in the U.S. All these trends are expected to increase demand for hemostatic agents.

Market Dynamics:

Driver:

Rising number of surgical procedures

As the global population grows and ages, the demand for surgical interventions continues to increase, spanning various medical fields, from cardiovascular and orthopedic surgeries to trauma and cancer-related procedures. Hemostatic agents play a crucial role in controlling bleeding during these surgeries, contributing to patient safety and surgical success. With advancements in surgical techniques and a broader array of surgical options available, the need for effective and efficient hemostatic tools becomes more pronounced. This growing surgical volume underscores the pivotal role hemostats play in maintaining hemostasis, reducing blood loss, and improving patient outcomes.

Restraint:

Limited use in emergency settings

While hemostatic agents are crucial in controlling bleeding during surgical procedures, their applicability in rapid and high-stress emergency situations, such as trauma care and battlefield medicine, can be restricted. In these scenarios, there is a need for hemostatic products that offer near-instantaneous and reliable hemostasis. Hemostats that require complex application procedures or specific conditions may not meet the demands of these critical situations. Overcoming this restraint requires the development of specialized hemostatic solutions designed for quick and effective use in emergencies, where every moment counts in saving lives and preventing severe hemorrhage.

Opportunity:

Healthcare cost reduction

By minimizing blood loss, reducing the need for blood transfusions, and shortening surgical times, hemostatic agents contribute to lower healthcare expenses. These cost-effective solutions improve resource allocation, reduce postoperative complications, and enhance patient outcomes, which can ultimately translate to reduced hospitalization costs and healthcare expenditures. In an environment where healthcare cost containment is a paramount concern, hemostatic products that offer both clinical effectiveness and economic advantages are well-positioned to address this opportunity and gain traction in the market.

Threat:

Stringent regulatory changes

Evolving regulations and heightened safety standards can impact the approval, formulation, and commercialization of hemostatic products. Compliance with these ever-changing regulations can be time-consuming and costly, leading to potential delays in market entry and increased development expenses. The challenge lies in adapting to new requirements while maintaining product safety and efficacy. Regulatory uncertainties and the need for comprehensive documentation add complexity to the development process. These factors can hinder innovation, limit the introduction of novel hemostatic solutions, and potentially reduce the market's ability to address the evolving needs of healthcare providers and patients.

COVID-19 Impact:

The COVID-19 pandemic had a mixed impact on the hemostats market. While the demand for hemostatic agents remained high during critical surgeries and trauma care, the pandemic disrupted supply chains, affecting the availability of some products. Additionally, elective surgical procedures were postponed or canceled, temporarily reducing the overall market demand. As healthcare facilities focused on COVID-19 treatment, the attention to other medical needs, including hemostasis, fluctuated. However, the importance of maintaining a robust healthcare infrastructure and the need for hemostats in emergencies became more evident, potentially driving greater resilience in the market post-pandemic as healthcare systems adapt to meet future challenges.

The thrombin-based hemostats segment is expected to be the largest during the forecast period

The thrombin-based hemostats segment is expected to have a lucrative growth. These products contain thrombin, an enzyme responsible for initiating the blood clotting process. When applied to a bleeding site, thrombin-based hemostats accelerate clot formation by converting soluble fibrinogen into insoluble strands of fibrin, ultimately leading to the formation of a stable blood clot. Their versatility makes them suitable for a wide range of surgical procedures, from cardiovascular and orthopedic surgeries to liver resections and trauma care. Thrombin-based hemostats offer rapid and precise control over bleeding, reducing the risk of hemorrhage and associated complications. Their proven track record in achieving hemostasis continues to make them a trusted choice in the medical field, contributing to their prominence within the broader hemostats market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These medical facilities, ranging from large academic medical centers to community hospitals, rely on hemostats to control bleeding during a diverse array of surgical procedures. Hemostatic agents are essential tools that ensure a bloodless surgical field, enabling healthcare providers to perform surgeries with precision and safety. The constant demand for surgical interventions, whether elective or emergency, underscores the importance of hemostats in hospitals. Moreover, the adoption of advanced surgical techniques, including minimally invasive procedures, further amplifies the need for effective hemostatic products, hospitals' ongoing focus on patient safety, successful surgical outcomes, and operational efficiency continues to drive the growth and development of the hemostats market.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region boasts a well-established healthcare infrastructure, advanced medical technology, and a high volume of surgical procedures. The demand for hemostatic agents and devices remains consistently strong across various medical specialties, from cardiac and orthopedic surgeries to trauma care. Stringent regulatory standards and a focus on patient safety drive the development and adoption of innovative hemostatic solutions. Additionally, the prevalence of chronic diseases and an aging population further amplifies the need for effective hemostats.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the market and is projected to have the highest CAGR over the forecast period. The increasing healthcare investments, expanding healthcare infrastructure, and a growing patient population create a favorable environment for the adoption of hemostatic agents and devices. With rising surgical volumes, particularly in countries like China and India, the demand for effective hemostatic solutions is on the ascent. Additionally, the region's focus on affordable healthcare solutions, growing trend of medical tourism and access to medical care drives the market's growth.

Key players in the market

Some of the key players in Hemostats market include: Ethicon, Inc, Becton Dickinson and Company, Marine Polymer Technologies, Inc, Pfizer, Inc, Johnson & Johnson Services, Inc, Integra Lifesciences Corporation, Hemostatis LLC, Z-Medica LLC, Medtronic plc, Gelita Medical GmbH, Stryker Corporation, Baxter International, Inc, Teleflex Incorporated, Anika Therapeutics, Inc, B. Braun Melsungen AG and CR Bard, Inc.

Key Developments:

In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.

In July 2023, Baxter International (US) launched its PERCLOT Absorbable Hemostatic Powder in the US. This will allow the company to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for patients.

Product Types Covered:

  • Thrombin-based Hemostats
  • Oxidized Regenerated Cellulose-based Hemostats
  • Combination Hemostats
  • Fibrin Sealants
  • Gelatin-based Hemostats
  • Collagen-based Hemostats
  • Other Product Types

Formulations Covered:

  • Matrix & Gel Hemostats
  • Sheet & Pad Hemostats
  • Sponge Hemostats
  • Powder Hemostats
  • Other Formulations

Indications Covered:

  • Closure
  • Surgery

Applications Covered:

  • Orthopedic Surgery
  • General Surgery
  • Neurological Surgery
  • Cardiovascular Surgery
  • Reconstructive Surgery
  • Gynecological Surgery
  • Plastic Surgery
  • Other Applications

End Users Covered:

  • Ambulatory Centers
  • Hospitals
  • Clinics
  • Community Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hemostats Market, By Product Type

  • 5.1 Introduction
  • 5.2 Thrombin-based Hemostats
  • 5.3 Oxidized Regenerated Cellulose-based Hemostats
  • 5.4 Combination Hemostats
  • 5.5 Fibrin Sealants
  • 5.6 Gelatin-based Hemostats
  • 5.7 Collagen-based Hemostats
  • 5.8 Other Product Types

6 Global Hemostats Market, By Formulation

  • 6.1 Introduction
  • 6.2 Matrix & Gel Hemostats
  • 6.3 Sheet & Pad Hemostats
  • 6.4 Sponge Hemostats
  • 6.5 Powder Hemostats
  • 6.6 Other Formulations

7 Global Hemostats Market, By Indication

  • 7.1 Introduction
  • 7.2 Closure
  • 7.3 Surgery

8 Global Hemostats Market, By Application

  • 8.1 Introduction
  • 8.2 Orthopedic Surgery
  • 8.3 General Surgery
  • 8.4 Neurological Surgery
  • 8.5 Cardiovascular Surgery
  • 8.6 Reconstructive Surgery
  • 8.7 Gynecological Surgery
  • 8.8 Plastic Surgery
  • 8.9 Other Applications

9 Global Hemostats Market, By End User

  • 9.1 Introduction
  • 9.2 Ambulatory Centers
  • 9.3 Hospitals
  • 9.4 Clinics
  • 9.5 Community Healthcare
  • 9.6 Other End Users

10 Global Hemostats Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Ethicon, Inc
  • 12.2 Becton Dickinson and Company
  • 12.3 Marine Polymer Technologies, Inc
  • 12.4 Pfizer, Inc
  • 12.5 Johnson & Johnson Services, Inc
  • 12.6 Integra Lifesciences Corporation
  • 12.7 Hemostatis LLC
  • 12.8 Z-Medica LLC
  • 12.9 Medtronic plc
  • 12.10 Gelita Medical GmbH
  • 12.11 Stryker Corporation
  • 12.12 Baxter International, Inc
  • 12.13 Teleflex Incorporated
  • 12.14 Anika Therapeutics, Inc
  • 12.15 B. Braun Melsungen AG
  • 12.16 CR Bard, Inc.

List of Tables

  • Table 1 Global Hemostats Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hemostats Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Hemostats Market Outlook, By Thrombin-based Hemostats (2021-2030) ($MN)
  • Table 4 Global Hemostats Market Outlook, By Oxidized Regenerated Cellulose-based Hemostats (2021-2030) ($MN)
  • Table 5 Global Hemostats Market Outlook, By Combination Hemostats (2021-2030) ($MN)
  • Table 6 Global Hemostats Market Outlook, By Fibrin Sealants (2021-2030) ($MN)
  • Table 7 Global Hemostats Market Outlook, By Gelatin-based Hemostats (2021-2030) ($MN)
  • Table 8 Global Hemostats Market Outlook, By Collagen-based Hemostats (2021-2030) ($MN)
  • Table 9 Global Hemostats Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 10 Global Hemostats Market Outlook, By Formulation (2021-2030) ($MN)
  • Table 11 Global Hemostats Market Outlook, By Matrix & Gel Hemostats (2021-2030) ($MN)
  • Table 12 Global Hemostats Market Outlook, By Sheet & Pad Hemostats (2021-2030) ($MN)
  • Table 13 Global Hemostats Market Outlook, By Sponge Hemostats (2021-2030) ($MN)
  • Table 14 Global Hemostats Market Outlook, By Powder Hemostats (2021-2030) ($MN)
  • Table 15 Global Hemostats Market Outlook, By Other Formulations (2021-2030) ($MN)
  • Table 16 Global Hemostats Market Outlook, By Indication (2021-2030) ($MN)
  • Table 17 Global Hemostats Market Outlook, By Closure (2021-2030) ($MN)
  • Table 18 Global Hemostats Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 19 Global Hemostats Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Hemostats Market Outlook, By Orthopedic Surgery (2021-2030) ($MN)
  • Table 21 Global Hemostats Market Outlook, By General Surgery (2021-2030) ($MN)
  • Table 22 Global Hemostats Market Outlook, By Neurological Surgery (2021-2030) ($MN)
  • Table 23 Global Hemostats Market Outlook, By Cardiovascular Surgery (2021-2030) ($MN)
  • Table 24 Global Hemostats Market Outlook, By Reconstructive Surgery (2021-2030) ($MN)
  • Table 25 Global Hemostats Market Outlook, By Gynecological Surgery (2021-2030) ($MN)
  • Table 26 Global Hemostats Market Outlook, By Plastic Surgery (2021-2030) ($MN)
  • Table 27 Global Hemostats Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global Hemostats Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Hemostats Market Outlook, By Ambulatory Centers (2021-2030) ($MN)
  • Table 30 Global Hemostats Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 Global Hemostats Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 32 Global Hemostats Market Outlook, By Community Healthcare (2021-2030) ($MN)
  • Table 33 Global Hemostats Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.